TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tum...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia Vol. 26; no. 2; pp. 236 - 243
Main Authors: Goh, K C, Novotny-Diermayr, V, Hart, S, Ong, L C, Loh, Y K, Cheong, A, Tan, Y C, Hu, C, Jayaraman, R, William, A D, Sun, E T, Dymock, B W, Ong, K H, Ethirajulu, K, Burrows, F, Wood, J M
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 01.02.2012
Nature Publishing Group
Subjects:
AML
CDK
ISSN:0887-6924, 1476-5551, 1476-5551
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first